EGFR and non-small cell lung carcinoma: These values were comparable to those of the reference inhibitor Erlotinib, an FDA-approved EGFR-targeting drug used in non-small cell lung carcinoma (-9.0 3 kcal/mol), indicating promising inhibitory potential.